BIOGEN INC. Operating Income
BIOGEN INC. (BIIB) reported Operating Income of $610.70 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-03.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2022-05-03
- BIOGEN INC. operating income (loss) for the quarter ending 2022-03-31 was $610.70M, a 37.29% decline year-over-year.
- BIOGEN INC. operating income (loss) for the quarter ending 2021-12-31 was $587.10M.
- BIOGEN INC. operating income (loss) for the quarter ending 2021-09-30 was $794.00M, a 26.91% decline year-over-year.
- BIOGEN INC. operating income (loss) for the quarter ending 2021-06-30 was $485.70M, a 75.40% decline year-over-year.
- BIOGEN INC. operating income (loss) for fiscal 2021 was $2.84B, a 37.57% decline from fiscal 2020.
- BIOGEN INC. operating income (loss) for fiscal 2020 was $4.55B, a 35.39% decline from fiscal 2019.
- BIOGEN INC. operating income (loss) for fiscal 2019 was $7.04B, a 19.60% increase from fiscal 2018.
- BIOGEN INC. operating income (loss) for fiscal 2018 was $5.89B, a 10.15% increase from fiscal 2017.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | $610.70M 10-Q · filed 2022-05-03 | $1.20B derived: sum of 2 quarters · filed 2022-05-03 | $1.99B derived: sum of 3 quarters · filed 2022-05-03 | $2.48B derived: sum of 4 quarters · filed 2022-05-03 | ||||
| 2021-12-31 | $587.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $1.38B derived: sum of 2 quarters · filed 2022-02-03 | $1.87B derived: sum of 3 quarters · filed 2022-02-03 | $2.84B 10-K · filed 2022-02-03 | ||||
| 2021-09-30 | $794.00M 10-Q · filed 2021-10-20 | $1.28B derived: sum of 2 quarters · filed 2021-10-20 | $2.25B 10-Q · filed 2021-10-20 | $1.92B derived: sum of 4 quarters · filed 2022-05-03 | ||||
| 2021-06-30 | $485.70M 10-Q · filed 2021-07-22 | $1.46B 10-Q · filed 2021-07-22 | $1.13B derived: sum of 3 quarters · filed 2022-05-03 | $2.22B derived: sum of 4 quarters · filed 2022-05-03 | ||||
| 2021-03-31 | $973.90M 10-Q · filed 2022-05-03 | $643.30M derived: sum of 2 quarters · filed 2022-05-03 | $1.73B derived: sum of 3 quarters · filed 2022-05-03 | $3.70B derived: sum of 4 quarters · filed 2022-05-03 | ||||
| 2020-12-31 | -$330.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $755.80M derived: sum of 2 quarters · filed 2022-02-03 | $2.73B derived: sum of 3 quarters · filed 2022-02-03 | $4.55B 10-K · filed 2022-02-03 | ||||
| 2020-09-30 | $1.09B 10-Q · filed 2021-10-20 | $3.06B derived: sum of 2 quarters · filed 2021-10-20 | $4.88B 10-Q · filed 2021-10-20 | $6.66B derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-06-30 | $1.97B 10-Q · filed 2021-07-22 | $3.79B 10-Q · filed 2021-07-22 | $5.57B derived: sum of 3 quarters · filed 2022-02-03 | $7.38B derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2020-03-31 | $1.82B 10-Q · filed 2021-04-22 | $3.60B derived: sum of 2 quarters · filed 2022-02-03 | $5.40B derived: sum of 3 quarters · filed 2022-02-03 | $7.36B derived: sum of 4 quarters · filed 2022-02-03 | ||||
| 2019-12-31 | $1.78B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $3.58B derived: sum of 2 quarters · filed 2022-02-03 | $5.54B derived: sum of 3 quarters · filed 2022-02-03 | $7.04B 10-K · filed 2022-02-03 | ||||
| 2019-09-30 | $1.81B 10-Q · filed 2020-10-21 | $3.76B derived: sum of 2 quarters · filed 2020-10-21 | $5.26B 10-Q · filed 2020-10-21 | $6.71B derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2019-06-30 | $1.96B 10-Q · filed 2020-07-22 | $3.46B 10-Q · filed 2020-07-22 | $4.90B derived: sum of 3 quarters · filed 2021-02-03 | $6.60B derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2019-03-31 | $1.50B 10-Q · filed 2020-04-23 | $2.95B derived: sum of 2 quarters · filed 2021-02-03 | $4.64B derived: sum of 3 quarters · filed 2021-02-03 | $5.86B derived: sum of 4 quarters · filed 2021-02-03 | ||||
| 2018-12-31 | $1.44B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $3.14B derived: sum of 2 quarters · filed 2021-02-03 | $4.35B derived: sum of 3 quarters · filed 2021-02-03 | $5.89B 10-K · filed 2021-02-03 | ||||
| 2018-09-30 | $1.70B 10-Q · filed 2019-10-22 | $2.91B derived: sum of 2 quarters · filed 2019-10-22 | $4.45B 10-Q · filed 2019-10-22 | $5.91B derived: sum of 4 quarters · filed 2020-02-06 | ||||
| 2018-06-30 | $1.21B 10-Q · filed 2019-07-24 | $2.75B 10-Q · filed 2019-07-24 | $4.21B derived: sum of 3 quarters · filed 2020-02-06 | $5.87B derived: sum of 4 quarters · filed 2020-02-06 | ||||
| 2018-03-31 | $1.53B 10-Q · filed 2019-04-24 | $3.00B derived: sum of 2 quarters · filed 2020-02-06 | $4.65B derived: sum of 3 quarters · filed 2020-02-06 | $5.86B derived: sum of 4 quarters · filed 2020-02-06 | ||||
| 2017-12-31 | $1.47B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $3.12B derived: sum of 2 quarters · filed 2020-02-06 | $4.32B derived: sum of 3 quarters · filed 2020-02-06 | $5.35B 10-K · filed 2020-02-06 | $5.34B 10-K · filed 2018-02-01 | |||
| 2017-09-30 | $1.65B 10-Q · filed 2018-10-23 | $1.65B 10-Q · filed 2017-10-24 | $2.85B derived: sum of 2 quarters · filed 2018-10-23 | $3.88B 10-Q · filed 2018-10-23 | $3.88B 10-Q · filed 2017-10-24 | $4.77B derived: sum of 4 quarters · filed 2019-02-06 | ||
| 2017-06-30 | $1.20B 10-Q · filed 2018-07-24 | $1.20B 10-Q · filed 2017-07-25 | $2.23B 10-Q · filed 2018-07-24 | $2.22B 10-Q · filed 2017-07-25 | $3.11B derived: sum of 3 quarters · filed 2019-02-06 | $4.54B derived: sum of 4 quarters · filed 2019-02-06 | ||
| 2017-03-31 | $1.02B 10-Q · filed 2018-04-24 | $1.02B 10-Q · filed 2017-04-25 | $1.91B derived: sum of 2 quarters · filed 2019-02-06 | $3.34B derived: sum of 3 quarters · filed 2019-02-06 | $4.80B derived: sum of 4 quarters · filed 2019-02-06 | |||
| 2016-12-31 | $887.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $2.31B derived: sum of 2 quarters · filed 2019-02-06 | $3.77B derived: sum of 3 quarters · filed 2019-02-06 | $5.15B 10-K · filed 2019-02-06 | $5.15B 10-K · filed 2017-02-02 | |||
| 2016-09-30 | $1.43B 10-Q · filed 2017-10-24 | $2.89B derived: sum of 2 quarters · filed 2017-10-24 | $4.26B 10-Q · filed 2017-10-24 | $5.43B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-06-30 | $1.46B 10-Q · filed 2017-07-25 | $2.84B 10-Q · filed 2017-07-25 | $4.01B derived: sum of 3 quarters · filed 2018-02-01 | $5.38B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-03-31 | $1.38B 10-Q · filed 2017-04-25 | $2.55B derived: sum of 2 quarters · filed 2018-02-01 | $3.92B derived: sum of 3 quarters · filed 2018-02-01 | $5.15B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2015-12-31 | $1.17B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $2.54B derived: sum of 2 quarters · filed 2018-02-01 | $3.77B derived: sum of 3 quarters · filed 2018-02-01 | $4.89B 10-K · filed 2018-02-01 | ||||
| 2015-09-30 | $1.37B 10-Q · filed 2016-10-26 | $1.37B 10-Q · filed 2015-10-21 | $2.60B derived: sum of 2 quarters · filed 2016-10-26 | $3.72B 10-Q · filed 2016-10-26 | $3.72B 10-Q · filed 2015-10-21 | $4.88B derived: sum of 4 quarters · filed 2017-02-02 | ||
| 2015-06-30 | $1.23B 10-Q · filed 2016-07-21 | $1.23B 10-Q · filed 2015-07-24 | $2.35B 10-Q · filed 2016-07-21 | $2.35B 10-Q · filed 2015-07-24 | $3.51B derived: sum of 3 quarters · filed 2017-02-02 | $4.66B derived: sum of 4 quarters · filed 2017-02-02 | ||
| 2015-03-31 | $1.12B 10-Q · filed 2016-04-21 | $1.12B 10-Q · filed 2015-04-24 | $2.28B derived: sum of 2 quarters · filed 2017-02-02 | $3.43B derived: sum of 3 quarters · filed 2017-02-02 | $4.42B derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2014-12-31 | $1.16B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $2.31B derived: sum of 2 quarters · filed 2017-02-02 | $3.30B derived: sum of 3 quarters · filed 2017-02-02 | $3.97B 10-K · filed 2017-02-02 | $3.97B 10-K · filed 2015-02-04 | |||
| 2014-09-30 | $1.15B 10-Q · filed 2015-10-21 | $2.14B derived: sum of 2 quarters · filed 2015-10-21 | $2.81B 10-Q · filed 2015-10-21 | $3.47B derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-06-30 | $988.73M 10-Q · filed 2015-07-24 | $1.66B 10-Q · filed 2015-07-24 | $2.32B derived: sum of 3 quarters · filed 2016-02-03 | $3.00B derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-03-31 | $671.35M 10-Q · filed 2015-04-24 | $1.33B derived: sum of 2 quarters · filed 2016-02-03 | $2.01B derived: sum of 3 quarters · filed 2016-02-03 | $2.68B derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2013-12-31 | $657.92M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $1.34B derived: sum of 2 quarters · filed 2016-02-03 | $2.00B derived: sum of 3 quarters · filed 2016-02-03 | $2.52B 10-K · filed 2016-02-03 | $2.52B 10-K · filed 2014-02-06 | |||
| 2013-09-30 | $684.53M 10-Q · filed 2014-10-22 | $1.35B derived: sum of 2 quarters · filed 2014-10-22 | $1.86B 10-Q · filed 2014-10-22 | $2.30B derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-06-30 | $662.53M 10-Q · filed 2014-07-23 | $1.17B 10-Q · filed 2014-07-23 | $1.62B derived: sum of 3 quarters · filed 2015-02-04 | $2.15B derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-03-31 | $510.52M 10-Q · filed 2014-04-23 | $956.03M derived: sum of 2 quarters · filed 2015-02-04 | $1.49B derived: sum of 3 quarters · filed 2015-02-04 | $2.00B derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2012-12-31 | $445.51M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $980.76M derived: sum of 2 quarters · filed 2015-02-04 | $1.49B derived: sum of 3 quarters · filed 2015-02-04 | $1.86B 10-K · filed 2015-02-04 | ||||
| 2012-09-30 | $535.25M 10-Q · filed 2013-10-28 | $1.04B derived: sum of 2 quarters · filed 2013-10-28 | $1.41B 10-Q · filed 2013-10-28 | $1.82B derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-06-30 | $505.72M 10-Q · filed 2013-07-25 | $875.09M 10-Q · filed 2013-07-25 | $1.28B derived: sum of 3 quarters · filed 2014-02-06 | $1.77B derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2012-03-31 | $369.37M 10-Q · filed 2013-04-25 | $778.47M derived: sum of 2 quarters · filed 2014-02-06 | $1.27B derived: sum of 3 quarters · filed 2014-02-06 | $1.68B derived: sum of 4 quarters · filed 2014-02-06 | ||||
| 2011-12-31 | $409.10M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $897.60M derived: sum of 2 quarters · filed 2014-02-06 | $1.31B derived: sum of 3 quarters · filed 2014-02-06 | $1.72B 10-K · filed 2014-02-06 | ||||
| 2011-09-30 | $488.49M 10-Q · filed 2012-10-25 | $899.31M derived: sum of 2 quarters · filed 2012-10-25 | $1.32B 10-Q · filed 2012-10-25 | $1.67B derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-06-30 | $410.81M 10-Q · filed 2012-07-24 | $827.10M 10-Q · filed 2012-07-24 | $1.18B derived: sum of 3 quarters · filed 2013-02-05 | $1.38B derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-03-31 | $416.28M 10-Q · filed 2012-05-01 | $771.47M derived: sum of 2 quarters · filed 2013-02-05 | $965.60M derived: sum of 3 quarters · filed 2013-02-05 | $1.36B derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2010-12-31 | $355.19M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $549.32M derived: sum of 2 quarters · filed 2013-02-05 | $945.20M derived: sum of 3 quarters · filed 2013-02-05 | $1.25B 10-K · filed 2013-02-05 | ||||
| 2010-09-30 | $194.13M 10-Q · filed 2011-10-28 | $590.01M derived: sum of 2 quarters · filed 2011-10-28 | $893.70M 10-Q · filed 2011-10-28 | $1.28B derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-06-30 | $395.88M 10-Q · filed 2011-07-26 | $699.57M 10-Q · filed 2011-07-26 | $1.08B derived: sum of 3 quarters · filed 2012-02-03 | $1.47B derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-03-31 | $303.69M 10-Q · filed 2011-04-21 | $687.07M derived: sum of 2 quarters · filed 2012-02-03 | $1.07B derived: sum of 3 quarters · filed 2012-02-03 | $1.29B derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2009-12-31 | $383.38M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $767.56M derived: sum of 2 quarters · filed 2012-02-03 | $990.47M derived: sum of 3 quarters · filed 2012-02-03 | $1.30B 10-K · filed 2012-02-03 | ||||
| 2009-09-30 | $384.18M 10-Q · filed 2010-10-26 | $607.09M derived: sum of 2 quarters · filed 2010-10-26 | $912.05M 10-Q · filed 2010-10-26 | $1.24B derived: sum of 4 quarters · filed 2011-02-04 | ||||
| 2009-06-30 | $222.91M 10-Q · filed 2010-07-20 | $527.87M 10-Q · filed 2010-07-20 | $852.83M derived: sum of 3 quarters · filed 2011-02-04 | $1.20B derived: sum of 4 quarters · filed 2011-02-04 | ||||
| 2009-03-31 | $304.96M 10-Q · filed 2010-04-20 | $629.92M derived: sum of 2 quarters · filed 2011-02-04 | $975.77M derived: sum of 3 quarters · filed 2011-02-04 | $1.27B derived: sum of 4 quarters · filed 2011-02-04 | ||||
| 2008-12-31 | $324.96M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $670.81M derived: sum of 2 quarters · filed 2011-02-04 | $967.61M derived: sum of 3 quarters · filed 2011-02-04 | $1.21B 10-K · filed 2011-02-04 | ||||
| 2008-09-30 | $345.85M 10-Q · filed 2009-10-21 | $642.65M derived: sum of 2 quarters · filed 2009-10-21 | $888.65M 10-Q · filed 2009-10-21 | |||||
| 2008-06-30 | $296.80M 10-Q · filed 2009-07-17 | $542.80M 10-Q · filed 2009-07-17 | ||||||
| 2007-12-31 | $779.77M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |